General Oncology Care in Morocco

Boutayeb, Saber; Majbar, Mohammed Anass

doi:10.1007/978-981-16-7945-2_11

Cited by 3 publications

(4 citation statements)

References 21 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observational retrospective, cohort study, had been conducted between November 22, 2021 and January 31, 2022, at the National Institute of Oncology-Rabat, one of the leading oncology centers in Morocco ( 11 ). Patients who have been visiting the Oncology Day Hospital to receive their therapy were recruited.…”

Section: Methodsmentioning

confidence: 99%

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report

Lamtai¹,

Boutayeb²,

Mrabti³

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundThe SARS-CoV-2 pandemic has slowed down cancer prevention and treatment strategies; consequently, cancer patients are prioritized to get the COVID-19 vaccines. Being constantly threatened by a new outbreak, the dive within the immunogenicity response is of great value; nonetheless, evaluating the side effects of these vaccines on fragile patients will assure their adherence to the vaccination protocol.ObjectivesThis study sets out to investigate the adverse events reported about the vaccine according to its doses and types, and to compare the prevalence and severity of toxicities across two subgroups of cancer patients, those who received the injection during active therapy cycles, and those who have not started the therapy yet at vaccination time, moreover, this paper examines the will and commitment of this population to the vaccination schemes.MethodsThis is an observational, retrospective, cohort study, in which we conducted a semi-constructed interview with 415 random solid cancer patients treated at the National Institute of Oncology in Morocco. The assessment of adverse events was carried out with a standardized scale.ResultsEleven months after the launch of the campaign, 75.2% of patients received at least one dose of the vaccine. Altogether, the analysis demonstrates a significant difference between the adverse effects reported post the second dose compared to the first one (p=0.004; odds ratio=2 [95% CI: 1.23 - 3.31]). Besides, the results indicate an increase in the rank of the severity of systemic events (p<0.001, r=0.28) after the second dose, but not for the local events (p=0.92, r=0.005). In the adjusted subgroup analysis, no effect was detected linking active therapy with the occurrence of toxicity (p=0.51, v=0.04) as well as with the level of severity reported after both; the first and second dose. Due to the fear of interactions with the therapy, we noticed a significant trend to delay the booster dose among the participants who completed the initial vaccine protocol.ConclusionA considerable body of evidence exists to persuade cancer patients to take the Coronavirus vaccines, and to also follow their vaccination schemes under the supervision of their treating physicians.

show abstract

Section: Methodsmentioning

confidence: 99%

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report

Lamtai¹,

Boutayeb²,

Mrabti³

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The burgeoning interest among interns and then residents in this nascent field greatly contributed to the creation of the medical oncology department at the National Institute of Oncology in Rabat. 2 The year 2008 was a landmark in Morocco, marking the graduation of the inaugural class of medical oncologists and the establishment of the Association for Training and Research in Medical Oncology. To our knowledge, this was the first network designed to unite medical oncologists committed to education, research, and patient care.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Building a United Front: Radiation Oncologists as Collaborative Partners, Not Competitors, to Medical Oncologists

Benhima,

El Bairi,

El Fadli

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

The current dynamic changes in the health care setting have seen the rise of specialized medical fields, significantly enhancing the quality of patient care. The shift from general surgery to fields focusing on distinct anatomic sites and the progression from internal medicine to subspecialties dedicated to specific health conditions have marked a new era in medicine. Oncology, in particular, has undergone a substantial transformation. Before 1960, surgery and radiation therapy were the only treatments available for treating cancer. The advent of chemotherapy in the 1960s constituted a major milestone in cancer treatment. 1 With the evolution of scientific knowledge in translational medicine, medical oncology has emerged as a distinct specialty. The massive developments in recent years have redefined cancer from an untreatable and incurable disease into a condition where active treatment provides control and extended survival and even cure.Amid the growing complexity of cancer care, medical oncologists stand at the crossroads of not only delivering clinical care to patients but also pioneering precision medicine approaches, engaging in preventive measures, providing palliative care, driving forward research initiatives, leading clinical trials implementation, and advocating for their patients. They act as the cornerstone in the multidisciplinary approach to cancer treatment, connecting groundbreaking research with daily patient care.Medical oncology was recognized as an independent specialty in Morocco by the Ministry of Health in 1994. However, it was not until 2004 that a significant development occurred with the establishment of the first structured 4-year residency training program in medical oncology at Mohammed V University in Rabat. Before this, medical oncology was nonexistent in Morocco, with no dedicated departments or qualifications and only a handful of privately practicing specialists trained abroad. The burgeoning interest among interns and then residents in this nascent field greatly contributed to the creation of the medical oncology department at the National Institute of Oncology in Rabat. 2 The year 2008 was a landmark in Morocco, marking the graduation of the inaugural class of medical oncologists and the establishment of the Association for Training and Research in Medical Oncology. To our knowledge, this was the first network designed to unite medical oncologists committed to education, research, and patient care. Today, the medical oncology community includes 15 active departments with over 200 specialists serving across 12 regions in Morocco. 2 However, since its creation, the journey toward establishing and legitimizing the practice of medical oncology has been fraught with challenges and resistance from within the medical community itself. Thirty years on, the field still faces its fair share of challenges. Among the most pressing issues for medical oncologists in Morocco is the continuous reluctance of other health care practitioners involved in cancer care to recognize the autonomy and...

show abstract

Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology

El Baraka,

Cherif Chefchaouni,

Bourdaime

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective Most intravenous anticancer drugs are administered in a dose per unit area or body weight, if not promptly administered to another patient cytotoxic leftover would be destroyed. To contain wastage, low-cost measures are highly desirable to contain and reduce expenditures without impairing the quality of care. The objective of the study is to evaluate the cost saved through the use of the two cytotoxic waste management techniques implemented in National Institute of Oncology’s centralized chemotherapy preparation unit, vial sharing and dose rounding. Method A 6-month prospective single centre study from 1 February to 1 August 2023 at the National Institute of Oncology of Rabat in Morocco. The number of prepared preparations and amount of drug saved by both vial sharing and dose rounding was collected using the centralized chemotherapy preparation unit’s ‘leftover tracking file’, the corresponding cost saved were calculated and then compared for each technique and with 2018 results. Results In total, 18,218 preparations were considered in the 6-month study. With the vial sharing technique 636,524.5 mg were saved corresponding to 246,031.4 (USD) saved cost, against 212,838.4 mg by dose rounding corresponding to 75,598.5 (USD) saved cost. This saving corresponded to a total of 321,629.4 (USD). Compared to the 2018 results leftovers costs saved by vial sharing corresponded to 289,972.05 (USD) by vial sharing technique for 1-year extrapolated period, and this study shows a saved cost of 321,629.9 (USD) by both vial sharing and dose rounding techniques. Conclusion Dose rounding technique combined with vial sharing allowed National Institute of Oncology’s centralized chemotherapy preparation unit to limit expensive cytotoxic cost wastage, highlighting these technique benefits.

show abstract

General Oncology Care in Morocco

Cited by 3 publications

References 21 publications

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report

Building a United Front: Radiation Oncologists as Collaborative Partners, Not Competitors, to Medical Oncologists

Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology

Contact Info

Product

Resources

About